This clean hepatic safety profile is reassuring and distinguishes orforglipron from the Pfizer candidates that failed in development
In other words, in the animal studies, there was one cancer that was identified, which is called medullary thyroid carcinoma, in certain animals
Rare but serious risks include pancreatitis and gallbladder disease
The FDA has reported multiple safety risks with theseand otherinjectable peptides, including the potential for immune reactions, cardiac events, and even death
New risks emerge for certain patients As GLP-1 drugs become more widely used across therapy areas, new risks are emerging, too
A patient starts with oral drops to experience the appetite suppression and confirm they tolerate the medication